{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 37,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a flow diagram to illustrate the randomization process and study timeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/35",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.895,
        "x": 0.105,
        "y": 0.285
      },
      "kind": "diagram",
      "text": "Randomization and treatment flow diagram",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3d18ad9-f9fe-4ff0-bfd3-acfdd217ca80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.875,
        "x": 0.062,
        "y": 0.865
      },
      "kind": "disclaimer",
      "text": "*Dosing is weekly and, if needed, dose is modified based on plasma arginine levels with maintenance of blinding. The first 8 weeks of the open-label extension will be blinded...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f362eca-e54d-4926-bbc4-606548ed6fd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.115,
        "w": 0.345,
        "x": 0.121,
        "y": 0.358
      },
      "kind": "list",
      "text": "Patients with ARG1-D: >=2 years old, Plasma arginine >250 uM, Baseline deficit in clinical response assessments",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75cb40fd-78a6-4491-ba20-32a3c5603238",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.46,
        "y": 0.665
      },
      "kind": "list",
      "text": "Analysis: Reduction of plasma arginine compared to placebo, Continuous analysis, Improvement compared to placebo",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acf14d51-6fa4-4b2f-953a-abe1cc8fb68a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.075,
        "y": 0.615
      },
      "kind": "list",
      "text": "Key Endpoints: Primary (Plasma arginine reduction), Secondary (GMFM-E, 2-Minute Walk Test)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cccd5388-c571-44fc-9c1f-e1a78b52bbd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.864,
        "x": 0.068,
        "y": 0.198
      },
      "kind": "title",
      "text": "Double-blind portion of trial complete – topline data announced December 2021",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46a09eae-3444-432e-8d6e-24f56af4ac03",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.391,
        "x": 0.068,
        "y": 0.048
      },
      "kind": "title",
      "text": "PEACE Phase 3 Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf84f637-8d0d-4ba7-b789-7d7f3cb6ba19",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "2ecc9b4b-3ae6-4277-aed9-6753365b4643",
      "evidence": "Standardized representation of patient cohorts, randomization, and endpoints.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}